AFC-HD AMS Life Science Co., Ltd. provided consolidated earnings guidance for the period ending August 31, 2022. For the period ending August 2022, the company expects consolidated net sales of JPY 22,500 million, operating profit of JPY 1,000 million, profit attributable to owners of parent of JPY 650 million or JPY 46.32 per basic share.